stereotactic
46 articles
ASCO GI Symposium Features a Broad Range of Pancreatic Cancer Research
Researchers at ASCO GI 2024 reported on research in health disparities, KRAS and other genetic mutations, and novel treatments.
Standard Chemotherapy Plus Novel Drugs for Advanced Pancreatic Cancer
This trial tests the effectiveness of three different novel drugs, including immunotherapy, added to standard treatment for advanced pancreatic cancer.
Multicenter Trial Focuses on Neoadjuvant Treatment for Borderline Resectable and Locally Advanced Disease
Dr. David Ryan outlines a new trial for pre-surgical pancreatic cancer treatment combining a blood pressure drug, immunotherapy, standard care and SBRT.
Aiming to Improve Immunotherapy for Pancreatic Cancer
Dr. Deirdre Cohen discusses clinical trials that aim to improve the effectiveness of immunotherapy for pancreatic cancer.
Looking Back at the Year in Research: 2019
Research highlights of 2019 include: approval of a PARP inhibitor, artificial intelligence to diagnose pancreatic cysts, and updated radiation guidelines.
New Data Support Preoperative Chemoradiation Regimen for Borderline Resectable Pancreatic Cancer
Should patients get chemotherapy or chemoradiation before surgery? Dr. Matthew Katz provides an update on the Alliance study.
Chemo and SBRT for Inoperable Pancreatic Cancer
For inoperable pancreatic cancer, researchers are comparing mFOLFIRINOX and SBRT with gemcitabine-based treatment regimens.
Testing Treatment Combinations to Make Surgery More Effective
Can losartan (a high blood pressure drug) and immunotherapy combined with standard chemotherapy and radiation be an effective combination against pancreatic cancer?